We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

5 hedge funds and large institutions have $6.01M invested in Seelos Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

173% more capital invested

Capital invested by funds: $2.2M → $6.01M (+$3.81M)

67% more funds holding

Funds holding: 3 → 5 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.12%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$2.13M
2
BlackRock
BlackRock
New York
+$164K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$164K

Top Sellers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
-$44K
2
TSS
Two Sigma Securities
New York
-$18K
3
UBS Group
UBS Group
Switzerland
-$9K
4
Bank of America
Bank of America
North Carolina
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$2.48M +$2.13M +13 New
SCM
2
Sarissa Capital Management
Connecticut
$2.48M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$620K +$164K +1 +50%
BlackRock
4
BlackRock
New York
$150K +$164K +1 New
Franklin Resources
5
Franklin Resources
California
$137K – – –
California Public Employees Retirement System
6
California Public Employees Retirement System
California
$44K – – –
Geode Capital Management
7
Geode Capital Management
Massachusetts
$42K – – –
Citadel Advisors
8
Citadel Advisors
Florida
$23K – – –
Northern Trust
9
Northern Trust
Illinois
$22K – – –
EWM
10
Evercore Wealth Management
New York
$5K – – –
Citigroup
11
Citigroup
New York
$3K – – –
FANJ
12
Financial Architects (New Jersey)
New Jersey
$3K – – –
Wells Fargo
13
Wells Fargo
California
$2K – – –
FDCDDQ
14
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.2K – – –
AG
15
Advisor Group
Arizona
$1K – – –
Group One Trading
16
Group One Trading
Illinois
$1K – – –
JP Morgan Chase
17
JP Morgan Chase
New York
$1K – – –
Morgan Stanley
18
Morgan Stanley
New York
$1K – – –
ARTA
19
A.R.T. Advisors
New York
– -$44K – –
Bank of America
20
Bank of America
North Carolina
– -$1K – –
TSS
21
Two Sigma Securities
New York
– -$18K – –
UBS Group
22
UBS Group
Switzerland
– -$9K – –

SEEL Hedge Fund Activity: Q3 2017 in Review

5 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2017, worth a combined $6.01M — up 173% from $2.2M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new SEEL positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $2.13M. The largest seller was A.R.T. Advisors, cutting an estimated $44K.

  • 5 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2017, up from 3 in Q2 2017.
  • Funds reported $6.01M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2017, up 173% quarter-over-quarter.
  • 2 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2017 and 0 closed out, a net change of +2 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2017 was Armistice Capital, an estimated $2.13M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2017 was A.R.T. Advisors, an estimated $44K sold.

Based on aggregated 13F filings for Q3 2017.